BeiGene, Ltd.

NasdaqGS:BGNE Stock Report

Market Cap: US$19.3b

BeiGene Valuation

Is BGNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BGNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BGNE ($181.62) is trading below our estimate of fair value ($498.96)

Significantly Below Fair Value: BGNE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BGNE?

Key metric: As BGNE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BGNE. This is calculated by dividing BGNE's market cap by their current revenue.
What is BGNE's PS Ratio?
PS Ratio6x
SalesCN¥23.51b
Market CapCN¥140.76b

Price to Sales Ratio vs Peers

How does BGNE's PS Ratio compare to its peers?

The above table shows the PS ratio for BGNE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.2x
NTRA Natera
14x12.4%US$21.4b
ALNY Alnylam Pharmaceuticals
15x22.3%US$31.4b
NBIX Neurocrine Biosciences
6.2x14.9%US$13.8b
UTHR United Therapeutics
5.8x8.2%US$16.1b
BGNE BeiGene
6x19.2%US$19.3b

Price-To-Sales vs Peers: BGNE is good value based on its Price-To-Sales Ratio (6x) compared to the peer average (10.2x).

Price to Sales Ratio vs Industry

How does BGNE's PS Ratio compare vs other companies in the US Biotechs Industry?

137 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.3x1.3%US$21.72b
MRNA Moderna
3x5.8%US$15.50b
INCY Incyte
3.3x8.9%US$13.47b
EXAS Exact Sciences
4x9.1%US$10.75b
BGNE 6.0xIndustry Avg. 9.9xNo. of Companies137PS01632486480+
137 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BGNE is good value based on its Price-To-Sales Ratio (6x) compared to the US Biotechs industry average (9.8x).

Price to Sales Ratio vs Fair Ratio

What is BGNE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BGNE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6x
Fair PS Ratio11.2x

Price-To-Sales vs Fair Ratio: BGNE is good value based on its Price-To-Sales Ratio (6x) compared to the estimated Fair Price-To-Sales Ratio (11.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BGNE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$181.62
US$280.92
+54.7%
13.6%US$376.00US$207.00n/a21
Dec ’25US$215.00
US$280.06
+30.3%
13.6%US$376.00US$207.00n/a22
Nov ’25US$204.21
US$276.99
+35.6%
15.1%US$345.00US$152.00n/a22
Oct ’25US$230.98
US$274.14
+18.7%
16.0%US$345.00US$152.00n/a22
Sep ’25US$191.78
US$272.96
+42.3%
16.7%US$345.00US$152.00n/a21
Aug ’25US$162.29
US$264.27
+62.8%
19.0%US$345.00US$152.00n/a20
Jul ’25US$144.89
US$267.01
+84.3%
18.2%US$345.00US$152.00n/a21
Jun ’25US$148.85
US$267.01
+79.4%
18.2%US$345.00US$152.00n/a21
May ’25US$156.53
US$268.40
+71.5%
19.2%US$345.00US$152.00n/a21
Apr ’25US$159.23
US$269.36
+69.2%
18.3%US$345.00US$161.00n/a21
Mar ’25US$165.02
US$270.08
+63.7%
17.4%US$345.00US$171.40n/a21
Feb ’25US$149.93
US$282.99
+88.7%
15.1%US$359.00US$196.00n/a19
Jan ’25US$180.36
US$285.19
+58.1%
15.3%US$359.00US$196.00n/a19
Dec ’24US$187.49
US$285.19
+52.1%
15.3%US$359.00US$196.00US$215.0019
Nov ’24US$181.30
US$287.65
+58.7%
16.4%US$359.00US$180.18US$204.2119
Oct ’24US$179.87
US$293.49
+63.2%
13.5%US$359.00US$196.00US$230.9820
Sep ’24US$208.92
US$295.74
+41.6%
13.1%US$359.00US$196.00US$191.7821
Aug ’24US$206.54
US$299.25
+44.9%
14.8%US$400.00US$196.00US$162.2921
Jul ’24US$178.30
US$308.39
+73.0%
12.9%US$400.00US$196.00US$144.8919
Jun ’24US$223.48
US$316.38
+41.6%
8.5%US$400.00US$263.30US$148.8520
May ’24US$259.98
US$310.77
+19.5%
9.6%US$400.00US$262.00US$156.5320
Apr ’24US$215.53
US$307.73
+42.8%
10.7%US$400.00US$230.10US$159.2321
Mar ’24US$235.88
US$310.06
+31.4%
10.9%US$400.00US$230.10US$165.0220
Feb ’24US$254.28
US$300.79
+18.3%
14.9%US$400.00US$213.00US$149.9319
Jan ’24US$219.94
US$264.98
+20.5%
18.1%US$400.00US$203.13US$180.3618
Dec ’23US$194.57
US$263.21
+35.3%
18.6%US$400.00US$203.13US$187.4918

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 04:23
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BeiGene, Ltd. is covered by 56 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Michael MengBOCI Research Ltd.
Yonglin YanBOCI Research Ltd.